Email this article Effectiveness of cisplatin monotherapy in standard-risk hepatoblastoma
- Authors: Moiseenko R.A.1, Akhaladze D.G.1, Filin A.V.2, Kim E.F.3, Rabaev G.S.1, Feoktistova E.V.4, Merkulov N.N.1, Metelin A.V.2, Tereshchenko G.V.1, Shchukin V.V.1, Shamanskaya T.V.1, Varfolomeeva S.R.5, Kachanov D.Y.1
-
Affiliations:
- Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
- B.V. Petrovsky National Scientific Center of Surgery
- Moscow City Oncology Hospital No. 62 of the Department of Health of Moscow
- Russian Children’s Clinical Hospital of the N.I. Pigorov Russian National Research Medical University of Ministry of Healthcare of the Russian Federation
- N.N. Blokhin National Medical Research Center of Oncology of Ministry of Healthcare of the Russian Federation
- Issue: Vol 21, No 4 (2022)
- Pages: 31-44
- Section: ORIGINAL ARTICLES
- Submitted: 29.04.2022
- Accepted: 11.05.2022
- Published: 26.12.2022
- URL: https://hemoncim.com/jour/article/view/606
- DOI: https://doi.org/10.24287/1726-1708-2022-21-4-31-44
- ID: 606
Cite item
Full Text
Abstract
Risk-adapted therapy is the standard of care for hepatoblastoma (HB). The aim of this study was to analyze the effectiveness of cisplatin monotherapy in patients with standard-risk HB. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation. For the period 02.2012–12.2019 (95 months) 60 patients with standard-risk HB aged 0–8 years were treated within the framework of the cooperation of Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation and B.V. Petrovsky Russian Scientific Center of Surgery. The SIOPEL criteria were used for stratification into risk groups. Throughout the study period, standard-risk patients received therapy per SIOPEL-3 SR protocol, including cisplatin monotherapy. Survival was assessed by the Kaplan–Meier method. For the purposes of this study, overall survival (OS), event-free survival (EFS), where any modification of chemotherapy regimen towards its escalation were considered as an additional event, and progression-free survival (PFS) were calculated. The survival analysis was carried out on 15.01.2021; 54/60 (90%) patients were treated with cisplatin monotherapy and included in the final analysis. Median age at diagnosis was 11.3 (range 0.0–87.7) months. Male:female ratio – 0.86:1. Distribution by PRETEXT stages: I – 14 (25.9%), II – 30 (55.6%), III – 10 (18.5%) patients. The median alphafetoprotein level at the time of diagnosis was 162 979 (range 129–2 000 000) ng/ml. Modification of therapy without confirmed relapse/progression was required in 3/54 patients. Median follow-up was 47.1 (range 2–99) months. Among 54 patients 52 (96.3%) are alive, 2 (3.7%) patients died (1/2 – complications of surgical treatment). Relapses/progressions were noted in 4/54 (7.4%) patients, one of whom died due to disease progression. The three-year OS was 98.1% (95% confidence interval (CI) 94.6–100), EFS – 85.1% (95% CI 75.5–94.6), PFS – 90.5% (95% CI 82.5–98.4). Our data are consistent with the original studies of the SIOPEL group and convincingly confirm the effectiveness of cisplatin monotherapy in patients with HB of the standard risk group in the Russian Federation. Currently this regimen is incorporated into the national clinical guidelines of HB therapy and considered as a standard of care.
Keywords
About the authors
R. A. Moiseenko
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
ORCID iD: 0000-0002-9654-084X
Moscow
Russian FederationD. G. Akhaladze
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
ORCID iD: 0000-0002-1387-209X
Moscow
Russian FederationA. V. Filin
B.V. Petrovsky National Scientific Center of Surgery
ORCID iD: 0000-0003-4205-5627
Moscow
Russian FederationE. F. Kim
Moscow City Oncology Hospital No. 62 of the Department of Health of Moscow
ORCID iD: 0000-0003-1806-9180
Krasnogorsk
Russian FederationG. S. Rabaev
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
ORCID iD: 0000-0002-5691-2522
Moscow
Russian FederationE. V. Feoktistova
Russian Children’s Clinical Hospital of the N.I. Pigorov Russian National Research Medical University of Ministry of Healthcare of the Russian Federation
ORCID iD: 0000-0003-2348-221X
Moscow
Russian FederationN. N. Merkulov
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
ORCID iD: 0000-0003-0404-6420
Moscow
Russian FederationA. V. Metelin
B.V. Petrovsky National Scientific Center of Surgery
ORCID iD: 0000-0002-2399-6811
Moscow
Russian FederationG. V. Tereshchenko
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
ORCID iD: 0000-0001-7317-7104
Moscow
Russian FederationV. V. Shchukin
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
ORCID iD: 0000-0002-7945-2565
Moscow
Russian FederationT. V. Shamanskaya
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
ORCID iD: 0000-0002-3767-4477
Moscow
Russian FederationS. R. Varfolomeeva
N.N. Blokhin National Medical Research Center of Oncology of Ministry of Healthcare of the Russian Federation
ORCID iD: 0000-0001-6131-1783
Moscow
Russian FederationD. Yu. Kachanov
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
Author for correspondence.
Email: Denis.Kachanov@fccho-moscow.ru
ORCID iD: 0000-0002-3704-8783
Denis Yu. Kachanov, Dr. Med. Sci., Head of the Department of Clinical Oncology, Deputy Director of the Institute of Oncology, Radiology and Nuclear Medicine
117997, Moscow, Samory Mashela St., 1
Russian FederationReferences
Supplementary files
